BLM and neoplasm: Thus, it is possible that 2ME2, ATTM or LCS-1 treatments in BLM- or CHEK2-deficient/defective tumors may induce anti-angiogenic effects that will synergize with the SL interactions to prevent tumor vascularization while inducing SL killing.